Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy - PubMed (original) (raw)
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy
Samuel T Workenhe et al. Cancer Immunol Res. 2013 Nov.
Abstract
Although antitumor activity of herpes simplex virus 1 (HSV-1) ICP0 null oncolytic vectors has been validated in murine breast cancer models, oncolytic virus treatment alone is insufficient to break immune tolerance. Thus, we investigated enhancing efficacy through combination therapy with the immunogenic cell death-inducing chemotherapeutic drug, mitoxantrone. Despite a lack of enhanced cytotoxicity in vitro, HSV-1 ICP0 null oncolytic virus KM100 with 5 μmol/L mitoxantrone provided significant survival benefit to BALB/c mice bearing Her2/neu TUBO-derived tumors. This protection was mediated by increased intratumoral infiltration of neutrophils and tumor antigen-specific CD8(+) T cells. Depletion studies verified that CD8-, CD4-, and Ly6G-expressing cells are essential for enhanced efficacy of the combination therapy. Moreover, the addition of mitoxantrone to KM100 oncolytic virus treatment broke immune tolerance in BALB-neuT mice bearing TUBO-derived tumors. This study suggests that oncolytic viruses in combination with immunogenic cell death-inducing chemotherapeutics enhance the immunogenicity of the tumor-associated antigens, breaking immunologic tolerance established toward these antigens.
©2013 AACR.
Similar articles
- Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A, Gambera S, Leo A, García-Castro J. Morales-Molina A, et al. J Immunother Cancer. 2021 Mar;9(3):e001703. doi: 10.1136/jitc-2020-001703. J Immunother Cancer. 2021. PMID: 33737338 Free PMC article. - Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS. Thomas S, et al. J Immunother Cancer. 2019 Aug 10;7(1):214. doi: 10.1186/s40425-019-0682-1. J Immunother Cancer. 2019. PMID: 31399043 Free PMC article. - Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9. Mol Ther. 2014. PMID: 24343053 Free PMC article. - Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P, Sampson V, Lettieri C, Kolb EA. Hingorani P, et al. Adv Exp Med Biol. 2014;804:259-83. doi: 10.1007/978-3-319-04843-7_14. Adv Exp Med Biol. 2014. PMID: 24924179 Review. - [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M, Huang C, Xia N. Hao M, et al. Bing Du Xue Bao. 2016 Jul;32(4):516-22. Bing Du Xue Bao. 2016. PMID: 29996042 Review. Chinese.
Cited by
- Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.
Inkol JM, Westerveld MJ, Verburg SG, Walsh SR, Morrison J, Mossman KL, Worfolk SM, Kallio KL, Phippen NJ, Burchett R, Wan Y, Bramson J, Workenhe ST. Inkol JM, et al. J Immunother Cancer. 2024 Apr 4;12(4):e006781. doi: 10.1136/jitc-2023-006781. J Immunother Cancer. 2024. PMID: 38580330 Free PMC article. - Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.
Taha Z, Crupi MJF, Alluqmani N, Fareez F, Ng K, Sobh J, Lee E, Chen A, Thomson M, Spinelli MM, Ilkow CS, Bell JC, Arulanandam R, Diallo JS. Taha Z, et al. Front Immunol. 2023 Apr 19;14:1181014. doi: 10.3389/fimmu.2023.1181014. eCollection 2023. Front Immunol. 2023. PMID: 37153626 Free PMC article. - Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C, Xiao G, Wang T, Song L, Peng B, Xu B, Zhang K. Fang C, et al. Research (Wash D C). 2023;6:0108. doi: 10.34133/research.0108. Epub 2023 Apr 3. Research (Wash D C). 2023. PMID: 37040283 Free PMC article. - Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells.
Davola ME, Cormier O, Vito A, El-Sayes N, Collins S, Salem O, Revill S, Ask K, Wan Y, Mossman K. Davola ME, et al. Cancers (Basel). 2023 Feb 17;15(4):1295. doi: 10.3390/cancers15041295. Cancers (Basel). 2023. PMID: 36831636 Free PMC article. - Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.
Hattinger CM, Salaroglio IC, Fantoni L, Godel M, Casotti C, Kopecka J, Scotlandi K, Ibrahim T, Riganti C, Serra M. Hattinger CM, et al. Int J Mol Sci. 2023 Jan 2;24(1):799. doi: 10.3390/ijms24010799. Int J Mol Sci. 2023. PMID: 36614241 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous